B3GAT1 and hepatocellular carcinoma: In subgroup analyses according to the types of cancer, the results indicated that CD57+ lymphocytes infiltrating into tumor significantly improved OS in hepatocellular cancer (HCC) (HR = 0.61, 95% CI 0.44 to 0.85, P = 0.003) and esophageal carcinoma (EC) (HR = 0.63, 95% CI 0.41 to 0.96, P = 0.033), with no heterogeneity being found (I2 = 0.0%, P = 0.882; I2 = 0.0%, P = 0.696 respectively) (Figure 2).